Wave Life Sciences(WVE)
$3.13-0.02 (-0.79%)
WVE
Wave Life Sciences stock drug pipeline
$3.13
At close:-0.02 (-0.79%)
Want to see WVE full AI Analyst Report?
Wave Life Sciences (WVE) Drug Pipeline
1,469 Followers
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Wve-N531 | Duchenne Muscular Dystrophy | Phase II | Not Yet Recruiting | Open-Label Extension Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy | Aug 14, 2025 | ― |
| Wve-007 | Obesity And Overweight | Phase I | Recruiting | A Phase 1 Study of WVE-007 in Adults Living with Overweight or Obesity | Jan 29, 2025 | ― |
| Wve-006 | Alpha-1 Antitrypsin Deficiency | phase1AndPhase2 | Recruiting | A Phase 1b/2a, Open-label Single Ascending Doses and Multiple Ascending Doses Study in Participants With Pi*ZZ AATD | May 03, 2024 | ― |
| Wve-006 | Alpha-1 Antitrypsin Deficiency | Phase I | Completed | A Phase 1 Research Study to Evaluate Safety, Tolerability, and Pharmacokinetics of WVE-006 in Healthy Participants With Wild-type AAT Expression (RestorAATion-1) | Nov 09, 2023 | ― |
| Sad: 30Mg Wve-003, Sad: 60Mg Wve-003, Sad: 90Mg Wve-003, Md: 30Mg Wve-003 | Huntington Disease | phase1AndPhase2 | Completed | Study of WVE-003 in Patients With Huntington's Disease | Aug 18, 2021 | ― |
| Wve-N531 | Duchenne Muscular Dystrophy | phase1AndPhase2 | Recruiting | Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53) | May 24, 2021 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Wve-N531 | Phase II | Duchenne Muscular Dystrophy | Not Yet Recruiting | Open-Label Extension Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy | Aug 14, 2025 | ― |
| Wve-007 | Phase I | Obesity And Overweight | Recruiting | A Phase 1 Study of WVE-007 in Adults Living with Overweight or Obesity | Jan 29, 2025 | ― |
| Wve-006 | phase1AndPhase2 | Alpha-1 Antitrypsin Deficiency | Recruiting | A Phase 1b/2a, Open-label Single Ascending Doses and Multiple Ascending Doses Study in Participants With Pi*ZZ AATD | May 03, 2024 | ― |
| Wve-006 | Phase I | Alpha-1 Antitrypsin Deficiency | Completed | A Phase 1 Research Study to Evaluate Safety, Tolerability, and Pharmacokinetics of WVE-006 in Healthy Participants With Wild-type AAT Expression (RestorAATion-1) | Nov 09, 2023 | ― |
| Sad: 30Mg Wve-003, Sad: 60Mg Wve-003, Sad: 90Mg Wve-003, Md: 30Mg Wve-003 | phase1AndPhase2 | Huntington Disease | Completed | Study of WVE-003 in Patients With Huntington's Disease | Aug 18, 2021 | ― |
| Wve-N531 | phase1AndPhase2 | Duchenne Muscular Dystrophy | Recruiting | Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53) | May 24, 2021 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Wave Life Sciences Pte. Ltd (WVE) have in its pipeline
Wave Life Sciences WVE is currently developing the following drugs: Wve-N531, Wve-007, Wve-006, Sad: 30Mg Wve-003, Sad: 60Mg Wve-003, Sad: 90Mg Wve-003, Md: 30Mg Wve-003. These drug candidates are in various stages of clinical development as the company works toward FDA approval.
